http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002114846-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2800-86 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-982 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-50 |
| filingDate | 2001-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50c88d40cfc662e1ba2c15b7f7d6dd44 |
| publicationDate | 2002-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2002114846-A1 |
| titleOfInvention | Amniotic apoptosis modulating substances |
| abstract | This invention is directed to methods of obtaining compounds from human amniotic tissue and/or by synthesizing these compounds by chemical and genetic engineering methods known in the art that modulate apoptosis in animals, including humans, their preparation, their applications in human conditions for the treatment of all disease conditions and other conditions in which apoptosis occurs and in laboratory tests for diagnostic studies and other potential uses. The invention describes methods of obtaining compositions that modulate apoptosis and compositions obtained thereby. These compositions are herein referred to as Amnion Apoptosis Modulators (AAM). AAM includes materials comprised of biologically active factors found in amniotic tissue and amniotic fluid associated therewith. AAM could be manufactured from the amniotic tissue of mammalian origin—human, pig etc. All AAMs, derived from amnions or chemically or genetically prepared are physiologically acceptable for administration in amount sufficient to modulate apoptosis. The invention encompasses methods of use of the AAMs. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005049638-A3 |
| priorityDate | 2000-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 591.